Our Team

Down

Turning Vision into Reality

Dr. Mehta brings over two decades of experience in the pharma and biotech industry, during which he has successfully designed and implemented innovative solutions, established global commercial operations, and led cross-functional teams. During his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in generating a range of value creation initiatives in corporate strategy and planning, global business development and corporate fundraising. He is a Co-founder, Chairman of the Board and Chief Executive Officer of BioXcel Corporation. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at Inpharmatica Ltd. and Jubilant Life Sciences. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation. Dr. Mehta holds a Ph.D. in chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in chemistry at the University of Montpellier, France.

Dr. Yocca is an accomplished R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has wide-ranging expertise in leading high performance, world-class teams in drug discovery and development whose efforts have resulted in a number of prominent neuroscience products including Buspar®, Serzone® Abilify® and Heltioz®. Frank has held various leadership roles at Astrazeneca and Bristol Myers Squibb. He is a recognized scientific leader in the neuroscience community and member of the Institute of Medicine of the National Academy of Science, and a Fellow of the American College of Neuropsychopharmacology. He has 45 referred articles, 96 abstracts and 65 invited presentations. Dr. Yocca holds a B.S. in biochemistry from Manhattan College and an M.S. in pharmacology and a Ph.D. in neuropharmacology for St. John's University.

Dr. O'Neill has proven expertise in therapeutic and diagnostic product development and has held senior leadership roles at global pharmaceutical companies, including Sanofi, Genentech and GlaxoSmithKline. Most recently, he served as Chief Medical Officer at Mirna Therapeutics and Exosome Diagnostics, where he oversaw global product development and medical affairs. At both Genentech and GlaxoSmithKline, he managed the clinical and biomarker development programs of several oncology therapeutic candidates. He was instrumental in the expanded approval of Genentech's Avastin® and Tarceva® oncology therapeutics. At GSK, he oversaw the signal transduction discovery unit and led the first IND application and clinical trial of the MEK inhibitor MEKINIST®. He has authored several peer-reviewed publications and conference presentations. Dr. O’Neill is also a member of the Royal College of Physicians. Dr. O’Neill received his M.D. and B.Sc. in molecular pathology from the University of Glasgow, Scotland.

Mr. Steinhart brings significant financial and strategic experience in the biotechnology and medical device industries. Prior to joining BioXcel Therapeutics, Richard served as Vice President and CFO at Remedy Pharmaceuticals, Inc., until it sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. Prior to joining Remedy Pharmaceuticals, Mr. Steinhart served as an independent consultant to biotechnology and medical device companies. Previously, Mr. Steinhart was the Senior Vice President, Finance and Chief Financial Officer of MELA Sciences. Prior to joining MELA Sciences, Mr. Steinhart held a variety of senior-level positions at Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies, Emisphere Technologies, Inc., and CW Group, Inc., a venture capital firm focused on medical technology. He began his career at PriceWaterhouseCoopers.

Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc. and Atossa Genetics, Inc. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant.

Mr. Mahadevan is responsible for leading the finance and accounting functions of the company and has extensive experience and knowledge of finance management in the software and pharmaceutical industries. Prior to joining BioXcel, Mr. Mahadevan was the Senior Vice President, Finance at GoldenSource Corp, an enterprise data management software company where he led the global finance and accounting team. Previously, he was the Director of Finance at inVentiv Health Inc. Mr. Mahadevan started his career at Ramco Systems, where he ultimately served as Head of Finance for the United States operations and the Finance Lead for the global aviation software segment. Mr. Mahadevan holds a B.S. in Commerce from Madras University. Mr. Mahadevan is a Certified Public Accountant in the United States and also a Chartered Accountant from India.

Leading with Passion

Dr. Peter Mueller is the President of R&D and Chief Scientific Officer at Axcella Health. Prior to joining Axcella, Dr. Mueller served as the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals where he provided strategic oversight for Vertex’s worldwide drug discovery and development programs. Under his leadership, the company secured approval for and launched two breakthrough drugs, INCIVEK® (HepC) in 2011, and KALYDECO® (CF) in 2012. Additionally, Vertex submitted both an NDA and MAA for ORKAMBI® (CF). Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc., where he played a key role in the development of Spiriva®, Combivent®, and Atrovent®. He is a member of various scientific and political societies, including the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (U.K.), IRI, RNA-Society, ASAP, AAAS (U.S.A.) and currently serves on the Boards of Directors and Scientific Advisory Boards of companies and organizations including US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, University Iowa (CBB), Keystone Symposia, Inhibikase Therapeutics, Inc., and Kaleido Biosciences, Inc. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.

Dr. Laumas is the founder and Chief Executive Officer of Bearing Circle Capital in Greenwich, Connecticut. He started his career at Goldman Sachs & Co. in New York in the Investment Banking Division. Dr. Laumas then joined Balyasny Asset Management in New York and later moved to North Sound Capital in Greenwich, Connecticut as a Managing Director responsible for global healthcare investments. Dr. Laumas has served as the executive chairman of Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) since 2014, a director of SRL Diagnostics Ltd., Asia’s largest clinical laboratory services company and as a director of Parkway Holdings Ltd. (IHH Healthcare: Singapore: IHH) (, Asia’s largest hospital company. Dr. Laumas has a unique industry perspective, particularly in both public and private investments and financial transactions in the healthcare arena. Dr. Laumas received his A.B. in chemistry from Cornell University in 1990, his M.D. from Albany Medical College, with a research year at the Dana-Farber Cancer Institute and completed his medical internship at the Yale University School of Medicine.

Dr. Mehta brings over two decades of experience in the pharma and biotech industry, during which he has successfully designed and implemented innovative solutions, established global commercial operations, and led cross-functional teams. During his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in generating a range of value creation initiatives in corporate strategy and planning, global business development and corporate fundraising. He is a Co-founder, Chairman of the Board and Chief Executive Officer of BioXcel Corporation. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at Inpharmatica Ltd. and Jubilant Life Sciences. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation. Dr. Mehta holds a Ph.D. in chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in chemistry at the University of Montpellier, France.

Dr. Nandabalan brings over two decades of experience across multiple functions in the pharmaceutical and biotechnology industries, including research & development, operations, and business development. He has extensive experience in M&A and in/out-licensing. He holds 12 issued patents and has published in leading journals such as Cell and Science. Dr. Nandabalan has garnered a deep understanding of market trends impacting the global healthcare environment, the pharma value chain, current unmet medical needs, and in the application of novel technologies to address these needs. Over the past ten years, he has led the pioneering development of big data analytics and machine learning at BioXcel, and its application in drug discovery and development. Dr. Nandabalan holds a B.Sc. and M.Sc. in agricultural science from Tamil Nadu Agricultural University and a Ph.D. in biochemistry and molecular biology from Indian Institute of Science.

Catalysts for Change

Dr. Gujrathi most recently served as Chief Medical Officer of Receptos, an immunology-focused biotechnology company that was acquired by Celgene in August 2015 for $7.2 billion. At Receptos, she built the clinical development organization and advanced the pipeline of drug candidates, including Phase 3 programs in multiple sclerosis and ulcerative colitis. Previously, Dr. Gujrathi was Vice President of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb (BMS). There she led late-stage clinical development and supported regulatory filings for Orencia® and Nulojix®. She was also responsible for development of other assets in the BMS immunology clinical pipeline, and advised the strategies for discovery, early development and external business development within the immunoscience franchise. Prior to BMS, Dr. Gujrathi held roles in the immunology, tissue growth and repair clinical development groups at Genentech and served as the Avastin franchise team leader. Earlier in her career, she was a management consultant in McKinsey & Company’s healthcare practice. Dr. Gujrathi received her B.S. in biomedical Engineering and M.D. from Northwestern University in the Honors Program in Medical Education. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School, and additional fellowship training in Allergy/Immunology at UCSF and Stanford. She previously served on the Board of Directors of Ambrx, which was acquired in June 2015.

Dr. Steven Paul brings to BioXcel Therapeutics more than 35 years of neuroscience expertise and an extensive track record in CNS drug discovery and development. Dr. Paul is the president and CEO of Voyager Therapeutics, a member of the Board of Directors and a venture partner at Third Rock Ventures. Preceding this appointment, Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including President of the Lilly Research Laboratories, and Vice President of discovery research and neuroscience research. As President of the Lilly Research Laboratories, he was responsible for the company’s overall R&D strategy, expanding its efforts in oncology and biotechnology, which resulted in a pipeline of approximately 70 new molecular entities. Dr. Paul currently serves on the Board of Directors of Sage Therapeutics and Alnylam Pharmaceuticals, and is a Chairman of the Board for the Foundation for the National Institutes of Health. Dr. Paul holds a B.A. in biology and psychology from Tulane University and an M.S. and M.D. from the Tulane University School of Medicine.